Lightbits Labs Named Storage Company of the Year and Receives Storage Hardware Award for SuperSSD NVMe/TCP at SDC Awards
3.12.2019 16:00:00 EET | Business Wire | Press release
At the recent SDC Awards gala here, Lightbits Labs took home two prestigious awards, Storage Company of the Year and Hardware Innovation of the Year. Lightbits received the nod for storage company of the year for its software defined storage (SDS) solution that brings hyperscale efficiency to on-premise cloud infrastructure with low-latency composable storage. Lightbits’ SuperSSD NVMe/TCP Storage Server , the World’s First Ultra-High Capacity, High Performance SSD Storage Appliance solution was selected as the most innovative hardware solution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191203005290/en/
Lightbits Labs takes home storage company of the year and wins storage hardware award for SuperSSD NVMe/TCP at the SDC Awards. Posing with the awards from left to right are: Kam Eshghi, Chief Strategy Officer, Shirley Kirzner, Eran Kirzner, Chief Executive Officer and Co-Founder, George Agasandian, Director of Solutions Engineering and Co-Founder, Ofir Efrati, VP of Engineering and Co-Founder, Shaul Galia, Chief Operations Officer, and Miki Avni, Chief Financial Officer. (Photo; Business Wire)
The SDC (Storage, Digitalization + Cloud) Awards, now in their 10th year, recognize and reward success in the products and services that are foundational to digital transformation. Lightbits received the honor for how the company is reimagining hyperscale storage for next-generation applications.
Co-founded by veteran Israeli entrepreneur and founder of Annapurna Avigdor Willenz, Lightbits introduced three groundbreaking technologies in its first year out of stealth mode: LightOS, LightField, and SuperSSD. The company was cited for its leadership in delivering software defined solution that runs on commodity hardware to disaggregate storage and compute over standard networks, allowing them to scale independently (increasing flexibility & efficiency) and maximizing resource utilization (lowering TCO) while delivering performance that is similar to direct-attached SSDs. Lightbits pioneered NVMe/TCP so its solution is easy to deploy at scale.
“Being recognized by our peers and voters from around the globe for this award highlights the increasingly important role of practical, smart and forward-thinking storage solutions for true digital transformation,” said Eran Kirzner, co-founder and CEO at Lightbits Labs. “Companies are responsible for vast amounts of data through both public and private clouds, and the volume of data continues to grow exponentially. We’re proud that our solutions are being recognized for their transformational role in addressing the data storage challenges that are so prevalent in enterprises today.”
In March 2019, Lightbits introduced its groundbreaking LightOS and LightField. The LightOS software and LightField storage acceleration card provide a high-performance, end-to-end disaggregation solution that can scale without requiring any changes to data center clients or network infrastructure. They were the industry’s first NVMe/TCP solutions to provide a Global Flash Translation Layer (GFTL) running over high-performance standard networks. The solutions allow private clouds and software-as-a-service (SaaS) providers to capitalize on the application performance of using local NVMe SSDs with the simplicity and efficiency of hyperscale solutions.
As trailblazers of a new storage paradigm, Lightbits’ solutions are successfully being used in industry-leading cloud data centers around the globe. The company is gaining industry recognition for its ground-breaking solutions and has received three industry awards over the past six months.
Lightbits Labs Resources
For additional information, contact info@lightibtslabs.com
About Lightbits Labs™
Lightbits Labs, founded in 2016, is remaking modern cloud infrastructure on a global scale. The company’s mission is to reinvent the way storage and networking are conducted in data centers. As trailblazers in this field, its solutions are successfully being used in industry-leading private cloud and enterprise data centers around the globe. With strategic investors including Dell Technology Capital and Micron, and with investments from Chairman and co-founder Avigdor Willenz, Lip-Bu Tan (CEO of Cadence and chairman of Walden International) and Marius Nacht, (Co-Founder and Chairman of Check Point Software), Lightbits Labs is disaggregating storage and compute to improve performance and TCO. Learn more at www.lightbitslabs.com or contact us at info@lightbitslabs.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191203005290/en/
Contact information
Alan Ryan/Marianne Dempsey
alanryan@rainierco.com/ mdempsey@rainierco.com
508-475-0025, ext. 116 or 115
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom